Deal talks between Genentech and Roche hit a snag over dueling interpretations of arcane SEC rules, but the problem is unlikely to derail the transaction, according to people familiar with the matter.
WSJ.com: What's News US, Wall Street Journal
Wed, 03/11/2009 - 9:26am
Deal talks between Genentech and Roche hit a snag over dueling interpretations of arcane SEC rules, but the problem is unlikely to derail the transaction, according to people familiar with the matter.